Obesogens: an emerging threat to public health
- PMID: 26829510
- PMCID: PMC4851574
- DOI: 10.1016/j.ajog.2016.01.182
Obesogens: an emerging threat to public health
Abstract
Endocrine disrupting chemicals (EDCs) are defined as exogenous chemicals, or mixtures of chemicals, that can interfere with any aspect of hormone action. The field of endocrine disruption is historically rooted in wildlife biology and reproductive endocrinology where EDCs are demonstrated contributors to infertility, premature puberty, endometriosis, and other disorders. Recently, EDCs have been implicated in metabolic syndrome and obesity. Adipose tissue is a true endocrine organ and, therefore, an organ that is highly susceptible to disturbance by EDCs. A subset of EDCs, called "obesogens," promote adiposity by altering programming of fat cell development, increasing energy storage in fat tissue, and interfering with neuroendocrine control of appetite and satiety. Obesity adds more than $200 billion to US healthcare costs and the number of obese individuals continues to increase. Hence, there is an urgent, unmet need to understand the mechanisms underlying how exposures to certain EDCs may predispose our population to be obese. In this review, we discuss the history of obesogen discovery from its origins in reproductive biology to its latest role in the transgenerational inheritance of obesity in mice. We discuss the development of adipose tissue in an embryo, maintenance of adipocyte number in adults, how EDC disruption programs stem cells to preferentially make more adipocytes, the mechanisms by which chemicals can permanently alter the germline epigenome, and whether there are barriers to EDCs in the gametes.
Keywords: adipogenesis; endocrine disruptors; metabolic disruptors; obesogens; transgenerational obesity.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
-
Moving from awareness to action on preventing patient exposure to toxic environmental chemicals.Am J Obstet Gynecol. 2016 May;214(5):555-8. doi: 10.1016/j.ajog.2016.03.029. Am J Obstet Gynecol. 2016. PMID: 27126615 Free PMC article. No abstract available.
-
Reply.Am J Obstet Gynecol. 2016 Oct;215(4):533. doi: 10.1016/j.ajog.2016.05.030. Epub 2016 May 27. Am J Obstet Gynecol. 2016. PMID: 27242202 No abstract available.
-
The endocrine disrupting chemicals as possible stillbirth contributors.Am J Obstet Gynecol. 2016 Oct;215(4):532-3. doi: 10.1016/j.ajog.2016.05.031. Epub 2016 May 27. Am J Obstet Gynecol. 2016. PMID: 27242205 No abstract available.
References
-
- Smith OW. Diethylstilbestrol in the prevention and treatment of complications of pregnancy. Am J Obstet Gynecol. 1948;56:821–34. - PubMed
-
- Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1509–14. - PubMed
-
- Palmer JR, Hatch EE, Rao RS, et al. Infertility among women exposed prenatally to diethylstilbestrol. Am J Epidemiol. 2001;154:316–21. - PubMed
-
- Kaufman RH, Adam E, Hatch EE, et al. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. Obstet Gynecol. 2000;96:483–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
